Interpace Biosciences Presented Two New Posters at the 2025 American Thyroid Association® (ATA) Annual Meeting
Interpace Biosciences (OTCQX: IDXG) presented two significant scientific posters at the 2025 American Thyroid Association Annual Meeting in Scottsdale, Arizona. The first poster demonstrated that their testing platform successfully yielded molecular results in 86% (56 out of 65) of thyroid FNA cases previously deemed insufficient by another platform, using archival cytology slides.
The second poster analyzed 28,144 indeterminate thyroid nodules, showing that ThyGeNEXT identified BRAF V600E-like alterations in 4-6% and RAS-like alterations in ~19% of cases, while 76-77% were mutation-negative. The ThyraMIRv2 microRNA profiling further refined malignancy risk assessment, with over 90% of mutation-negative nodules classified as low risk.
Interpace Biosciences (OTCQX: IDXG) ha presentato due poster scientifici significativi durante il 2025 American Thyroid Association Annual Meeting a Scottsdale, in Arizona. Il primo poster ha dimostrato che la loro piattaforma di test ha fornito con successo risultati molecolari nell'86% (56 su 65) dei casi di aspirato tiroideo (FNA) precedentemente ritenuti insufficienti da un'altra piattaforma, utilizzando vetrini di citologia d'archivio.
Il secondo poster ha analizzato 28.144 noduli tiroidei indeterminati, mostrando che ThyGeNEXT ha identificato alterazioni simili a BRAF V600E in 4-6% e alterazioni di tipo RAS in circa 19% dei casi, mentre 76-77% erano negativi per mutazioni. Il profilo microRNA ThyraMIRv2 ha ulteriormente affinato la valutazione del rischio di malignità, con oltre 90% dei noduli negativi per mutazioni classificati come a basso rischio.
Interpace Biosciences (OTCQX: IDXG) presentó dos pósteres científicos significativos en la Reunión Anual 2025 de la American Thyroid Association en Scottsdale, Arizona. El primer póster demostró que su plataforma de pruebas generó con éxito resultados moleculares en el 86% (56 de 65) de los casos de aspirado FNA tiroideo previamente considerados insatisfactorios por otra plataforma, utilizando láminas de citología archivadas.
El segundo póster analizó 28.144 nódulos tiroideos indeterminados, mostrando que ThyGeNEXT identificó alteraciones tipo BRAF V600E en 4-6% y alteraciones tipo RAS en ~19% de los casos, mientras que el 76-77% fueron negativos para mutaciones. El perfil de microRNA ThyraMIRv2 refinó aún más la evaluación del riesgo de malignidad, con más del 90% de los nódulos negativos a mutaciones clasificados como de bajo riesgo.
Interpace Biosciences (OTCQX: IDXG)가 Arizona주 Scottsdale에서 열린 2025년 미국 갑상선 협회 연례 회의에서 두 편의 중요한 과학 포스터를 발표했습니다. 첫 번째 포스터는 다른 플랫폼에서 불충분하다고 판단된 86%(65건 중 56건)의 갑상선 FNA 사례에서 성공적으로 분자 결과를 산출했음을 보여주었으며, 보관된 세포학 슬라이드를 사용했습니다.
두 번째 포스터는 28,144건의 불확정 갑상선 결절을 분석했으며 ThyGeNEXT가 4-6%의 사례에서 BRAF V600E와 유사한 변화, 약 19%에서 RAS 유사 변화를 확인했고, 76-77%는 돌연변이가 없었습니다. ThyraMIRv2 마이크로RNA 프로파일링은 악성 위험 평가를 더욱 정밀하게 다듬어, 변이가 없는 결절의 90% 이상이 낮은 위험으로 분류되었습니다.
Interpace Biosciences (OTCQX: IDXG) a présenté deux affiches scientifiques importantes lors de la Réunion Annuelle 2025 de l'American Thyroid Association à Scottsdale, en Arizona. La première affiche a démontré que leur plateforme de tests fournissait avec succès des résultats moléculaires dans 86% (56 sur 65) des cas de FNA thyroïdienne jugés insuffisants par une autre plateforme, en utilisant des lames de cytologie archivées.
La seconde affiche a analysé 28 144 nodules thyroïdiens indéterminés, montrant que ThyGeNEXT identifiait des altérations similaires à BRAF V600E dans 4-6% et des altérations de type RAS dans environ 19% des cas, tandis que 76-77% étaient négatifs pour mutations. Le profilage microARN ThyraMIRv2 a encore affiné l’évaluation du risque de malignité, avec plus de 90% des nodules négatifs pour mutations classés comme à faible risque.
Interpace Biosciences (OTCQX: IDXG) präsentierte zwei bedeutende wissenschaftliche Poster auf der 2025 American Thyroid Association Annual Meeting in Scottsdale, Arizona. Das erste Poster zeigte, dass ihre Testplattform erfolgreich molekulare Ergebnisse in 86% (56 von 65) der Thyroidea-FNA-Fälle lieferte, die von einer anderen Plattform zuvor als unzureichend eingestuft wurden, unter Verwendung archivierter Zytologie-Folien.
Das zweite Poster analysierte 28.144 indeterminierte Schilddrüsenknoten und zeigte, dass ThyGeNEXT BRAF V600E-ähnliche Veränderungen in 4-6% und RAS-ähnliche Veränderungen in ca. 19% der Fälle identifizierte, während 76-77% mutation-negativ waren. Das ThyraMIRv2-MikroRNA-Profiling verfeinerte die Einschätzung des Malignitätsrisikos weiter, wobei über 90% der mutation-negativen Knoten als niedriges Risiko eingestuft wurden.
Interpace Biosciences (OTCQX: IDXG) قدمت اثنين من الملصقات العلمية المهمة في الاجتماع السنوي للجمعية الأمريكية للغدة الدرقية 2025 في سكوتسديل بولاية أريزونا. أظهر الملصق الأول أن منصتهم الاختبارية أمنت نتائج جزيئية بنجاح في 86% (56 من 65) من حالات FNA الغدية التي اعتُبرت سابقاً غير كافية من قبل منصة أخرى، باستخدام شرائح علم الخلايا المؤرشفة.
أما الملصق الثاني فقام بتحليل 28,144 عقدة غدية غير محددة، مبيناً أن ThyGeNEXT حدد تغيرات تشبه BRAF V600E في 4-6% و تغيرات تشبه RAS في نحو 19% من الحالات، بينما كانت نسبة 76-77% سلبيّة للطفرات. كما قام تخصيص ThyraMIRv2 لمضاد الميكروRNA بتحسين تقدير مخاطر الأورام، حيث تم تصنيف أكثر من 90% من العقد الغدية الخالية من الطفرات كخطر منخفض.
Interpace Biosciences (OTCQX: IDXG) 在美国甲状腺协会年度会议（2025）期间于亚利桑那州斯科茨代尔发布了两份重要的科学海报。第一份海报显示，他们的检测平台在另一平台此前被判定为不充分的 86%（56/65） 的甲状腺FNA病例中成功获得分子结果，使用的是归档的细胞学载玻片。
第二份海报分析了 28,144 例不确定性甲状腺结节，显示 ThyGeNEXT 在 4-6% 的病例中识别出类似 BRAF V600E 的改变，在约 19% 的病例中识别出 RAS 类改变，而 76-77% 无突变。ThyraMIRv2 微RNA 分型进一步细化了恶性风险评估，超过 90% 的无突变结节被归类为低风险。
- None.
- None.
Highlights
- Independent institutional experience shows archival cytology slides enabled successful molecular results in cases previously insufficient for testing by another commercially available molecular diagnostic test, helping avoid repeat FNAs
- Large real-world analysis (n=28,144) demonstrates how ThyGeNEXT® + ThyraMIR®v2 refines risk in Bethesda III/IV nodules, especially in RAS-like and mutation-negative cases
- Presentations were held during the ATA Annual Meeting, September 10–14, 2025, at the Westin Kierland in Scottsdale, Arizona
PARSIPPANY, NJ, Sept. 15, 2025 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) presented two new scientific posters at the 2025 American Thyroid Association® (ATA) Annual Meeting in Scottsdale, Arizona, September 10–14, 2025.
The first poster, “Utilizing Archival Cytology Slides to Overcome Molecular Testing Insufficiency Rates in Cytologically Indeterminate Thyroid Nodules: An Institutional Experience” (Poster #478), led by Temma Kaufman, MD (Associated Pathologists PA, BayCare St. Joseph’s Hospital), described a hospital-system-wide quality-improvement effort. Among 65 thyroid FNA cases previously deemed insufficient for another testing platform, 56 (
The second poster, “Refined Risk Stratification of Bethesda III/IV Thyroid Nodules Using ThyGeNEXT® and ThyraMIR®v2” (Poster #477), reported outcomes from 28,144 indeterminate (Bethesda III/IV) nodules tested between September 2022 and April 2025. ThyGeNEXT identified BRAF V600E-like alterations in ~
“These data continue to validate the real-world utility of our combination platform,” said Tom Burnell, PhD, President & Chief Executive Officer of Interpace Biosciences. “The independent institutional experience highlights practical advantages—like testing from archival cytology slides—that can reduce repeat procedures, while our 28,000-plus case analysis demonstrates how integrating DNA mutations with microRNA expression refines risk where clinicians need it most.”
“Across our health system, moving to a platform that accepts archival cytology slides made a meaningful difference,” said Temma Kaufman, MD, Associated Pathologists PA, BayCare St. Joseph’s Hospital. “We were able to obtain actionable molecular results in many cases that were initially insufficient by another testing method, helping us avoid additional FNAs and provide clearer guidance for patient care.”
About ThyGeNEXT and ThyraMIRv2
Interpace’s unique combination platform integrates next-generation DNA/RNA mutation analysis (ThyGeNEXT) with proprietary microRNA pairwise expression profiling (ThyraMIRv2) to refine malignancy risk—particularly in RAS-like and mutation-negative indeterminate nodules—supporting more informed clinical decisions.
About Interpace Biosciences
Interpace Biosciences is an emerging leader in enabling personalized medicine, offering specialized services along the therapeutic value chain from early diagnosis and prognostic planning to targeted therapeutic applications.
Clinical services, through Interpace Diagnostics, provide clinically useful molecular diagnostic tests and bioinformatics and pathology services for evaluating risk of cancer by leveraging the latest technology in personalized medicine for improved patient diagnosis and management. Interpace has two commercialized molecular tests: ThyGeNEXT for the diagnosis of thyroid cancer from thyroid nodules utilizing a next-generation sequencing assay and ThyraMIRv2, used in combination with ThyGeNEXT, for the diagnosis of thyroid cancer utilizing a proprietary microRNA pairwise expression profiler along with algorithmic classification.
For more information, please visit Interpace Biosciences’ website at www.interpace.com.
Forward-looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, relating to the Company’s future financial and operating performance. The Company has attempted to identify forward-looking statements by terminology including “believes,” “estimates,” “anticipates,” “expects,” “plans,” “projects,” “intends,” “potential,” “may,” “could,” “might,” “will,” “should,” “approximately” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are based on current expectations, assumptions and uncertainties involving judgments about, among other things, future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond the Company’s control. These statements also involve known and unknown risks, uncertainties and other factors that may cause the Company’s actual results to be materially different from those expressed or implied by any forward-looking statements, including, but not limited to, the possibility that the Company’s estimates of future revenue, cash flows and adjusted EBITDA may prove to be materially inaccurate, the Company’s prior history of operating losses, the Company’s ability to adequately finance its business and seek alternative sources of financing, the Company’s ability to repay borrowings from BroadOak, the Company’s dependence on sales and reimbursements from its clinical services, the Company’s ability to retain or secure reimbursement including its reliance on third parties to process and transmit claims to payers and the adverse impact of any delay, data loss, or other disruption in processing or transmitting such claims, the Company’s revenue recognition being based in part on estimates for future collections which estimates may prove to be incorrect, and the Company’s ability to restructure itself in light of the loss of reimbursement for its PancraGEN product.
Additionally, all forward-looking statements are subject to the “Risk Factors” detailed from time to time in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, as amended, Current Reports on Form 8-K and Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission. Because of these and other risks, uncertainties and assumptions, undue reliance should not be placed on these forward-looking statements. In addition, these statements speak only as of the date of this press release and, except as may be required by law, the Company undertakes no obligation to revise or update publicly any forward-looking statements for any reason.
Contacts:
Investor Relations
Interpace Biosciences, Inc.
(855)-776-6419
Info@Interpace.com
FAQ
What were the key findings from Interpace Biosciences' (IDXG) presentations at the 2025 ATA Meeting?
How does Interpace's ThyGeNEXT + ThyraMIR testing improve thyroid nodule analysis?
What percentage of thyroid nodules were successfully analyzed using Interpace's testing platform?
What is the clinical significance of Interpace's thyroid testing results?
How many cases were included in Interpace's thyroid nodule analysis study?
